» Articles » PMID: 28360520

Human Cytotoxic T-lymphocyte Membrane-camouflaged Nanoparticles Combined with Low-dose Irradiation: a New Approach to Enhance Drug Targeting in Gastric Cancer

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2017 Apr 1
PMID 28360520
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Cell membrane-derived nanoparticles are becoming more attractive because of their ability to mimic many features of their source cells. This study reports on a biomimetic delivery platform based on human cytotoxic T-lymphocyte membranes. In this system, the surface of poly-lactic--glycolic acid nanoparticles was camouflaged using T-lymphocyte membranes, and local low-dose irradiation (LDI) was used as a chemoattractant for nanoparticle targeting. The T-lymphocyte membrane coating was verified using dynamic light scattering, transmission electron microscopy, and confocal laser scanning microscopy. This new platform reduced nanoparticle phagocytosis by macrophages to 23.99% (=0.002). Systemic administration of paclitaxel-loaded T-lymphocyte membrane-coated nanoparticles inhibited the growth of human gastric cancer by 56.68% in Balb/c nude mice. Application of LDI at the tumor site significantly increased the tumor growth inhibition rate to 88.50%, and two mice achieved complete remission. Furthermore, LDI could upregulate the expression of adhesion molecules in tumor vessels, which is important in the process of leukocyte adhesion and might contribute to the localization of T-lymphocyte membrane-encapsulated nanoparticles in tumors. Therefore, this new drug-delivery platform retained both the long circulation time and tumor site accumulation ability of human cytotoxic T lymphocytes, while local LDI could significantly enhance tumor localization.

Citing Articles

Improving systemic delivery of oncolytic virus by cellular carriers.

Peng Z, Kalim M, Lu Y Cancer Biol Med. 2025; 21(12).

PMID: 39831754 PMC: 11745088. DOI: 10.20892/j.issn.2095-3941.2024.0390.


Biomimetic nanocarriers: integrating natural functions for advanced therapeutic applications.

Perini H, Matos B, de Oliveira C, da Silva M Beilstein J Nanotechnol. 2024; 15:1619-1626.

PMID: 39717696 PMC: 11665443. DOI: 10.3762/bjnano.15.127.


Innovative utilization of cell membrane-coated nanoparticles in precision cancer therapy.

He Y, Zhang S, She Y, Liu Z, Zhu Y, Cheng Q Exploration (Beijing). 2024; 4(6):20230164.

PMID: 39713200 PMC: 11655310. DOI: 10.1002/EXP.20230164.


Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy.

Longobardi G, Moore T, Conte C, Ungaro F, Satchi-Fainaro R, Quaglia F Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(5):e1990.

PMID: 39217459 PMC: 11670051. DOI: 10.1002/wnan.1990.


Histochemistry for Molecular Imaging in Nanomedicine.

Malatesta M Int J Mol Sci. 2024; 25(15).

PMID: 39125610 PMC: 11311594. DOI: 10.3390/ijms25158041.


References
1.
Zhu W, Xua D, Pu J, Zong C, Li T, Tao G . A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012; 104(3):361-6. DOI: 10.1016/j.radonc.2012.08.024. View

2.
Murad A, Santiago F, Petroianu A, Rocha P, Rodrigues M, Rausch M . Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993; 72(1):37-41. DOI: 10.1002/1097-0142(19930701)72:1<37::aid-cncr2820720109>3.0.co;2-p. View

3.
Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

4.
Baggiolini M . Chemokines and leukocyte traffic. Nature. 1998; 392(6676):565-8. DOI: 10.1038/33340. View

5.
Roy A, Singh M, Upadhyay P, Bhaskar S . Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. Int J Pharm. 2013; 445(1-2):171-80. DOI: 10.1016/j.ijpharm.2013.01.045. View